Huntington's Disease Therapeutics: A Global Market Report
San Jose, CA (PRWEB) April 7, 2010
Huntington's disease (HD) is a rare, chronic, incurable, progressive and disabling neurological condition, which continues to challenge the medical community. About 30,000 Americans (or 1 in 10,000 people) have Huntington's disease and at least 150,000 individuals have a 50% chance of inheriting the disease. The symptoms of HD become most evident in adulthood, typically 30 to 55 years, characterized by sudden, abnormal, and uncontrolled jerky movements called chorea. Currently, therapeutics for HD is limited only to symptomatic treatments and there are no treatment options with proven safety and efficacy to slowdown disease progression or enhance survival rate. Global HD therapeutics market is vastly underserved with only one approved product, Xenazine® (Nitoman® in Canada) being indicated for the treatment of Huntington's chorea. Also, R&D in this area confronts its toughest challenge ever, with opportunities for major investments still restricted due to Huntington's orphan disease status.
Off-label use of medications is of utmost importance to the Huntington's Disease community due to lack of effective on-label alternatives. Various anti-cholinergics and anti-psychotics have long been prescribed 'off-label' for the treatment of emotional disturbances as well as motor impairment characteristic of the disorder. However, side effects associated with most widely prescribed anti-psychotic and anti-epilepsy drugs further add to the woes of unmet patient needs in treatment of Huntington's disease. Such a situation has necessitated manufacturers to boost R&D spending to quickly transform their concepts into proprietary technologies and innovative solutions. As stated by the new market research report on Huntington's Disease Therapeutics, the market is expected to reach US$634.2 million by 2015. Strong drug pipeline, high physician/patient acceptance of new drugs, and improved safety, efficacy profiles of newly developed drugs, bode well for the market in the upcoming years.
Players in the marketplace include Alnylam Pharmaceuticals Inc, Amarin Corporation Plc, Avicena Group Inc, Biovail Corporation, Cambridge Laboratories Group Limited, Ceregene Inc, Cortex Pharmaceuticals Inc, H. Lundbeck A/S, Medivation Inc, NeuroSearch A/S, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp, Targeted Genetics Corporation, Trophos SA, and Vertex Pharmaceuticals Incorporated, among others.
The report titled "Huntington's Disease Therapeutics: A Global Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, product overview, product introductions/innovations, profiles of major players, and recent industry activity. The single segment report quantifies latent demand in value sales for the global market.
For more details about this market research report, please visit -
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com